Thomas Hach
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Iptacopan in IgA Nephropathy - Final 24-Month Data.
Journal: The New England journal of medicine
Published: March 30, 2026
Iptacopan in Patients With IgA Nephropathy From East Asia.
Journal: Kidney international reports
Published: August 19, 2025
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Journal: The New England journal of medicine
Published: October 25, 2024
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
Published: December 01, 2022
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: June 27, 2022
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 05, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 09, 2022
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: January 14, 2022
Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: September 03, 2021
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Journal: Journal of neurology
Published: August 24, 2021
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
Journal: Journal of medical Internet research
Published: April 13, 2021
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 24, 2021
Last Updated: 09/26/2026